SALE
市場調查報告書

免疫抑制劑API (原料藥)的全球市場 - 預測與機會:2025年

Global Immunosuppressants API Market By Method, By Application, By Type, By Product, By APIs, By End User, By Region, Competition, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 934751
出版日期 內容資訊 英文 111 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

免疫抑制劑API (原料藥)的全球市場 - 預測與機會:2025年 Global Immunosuppressants API Market By Method, By Application, By Type, By Product, By APIs, By End User, By Region, Competition, Forecast & Opportunities, 2025
出版日期: 2020年05月01日內容資訊: 英文 111 Pages
簡介

全球免疫抑制劑API (原料藥) 市場,主要由於再生醫療 (組織工程)的持續性技術的進步,在預測期間內預計以壓倒性的速度成長。再加上多發性硬化症,圓形脫髮症,關節炎等自體免疫疾病的發生率劇增,給予市場成長積極的影響。還有全世界的肝臟移植和腎臟移植等器官移植的增加,今後數年市場的預計更加快速成長。但,今後數年的全球免疫抑制劑API市場成長的主要阻礙因素中,包含API相關的高成本和器官捐贈者的可用性的缺乏。

全球免疫抑制劑API市場,區隔為各方法,各用途,各類型,各產品,各API,各終端用戶,各地區市場。各產品分類為錠劑、膠囊、液體、注射市場。預計這個期間,錠劑市場區隔主導目前的市場,主要由於成本效果高的製造流程,加上為了使保存期更長,在預測期間內也維持龍頭地位。再加上錠劑能包含比膠囊更高用量的有效成分,今後數年更預期將推動市場區隔的成長。

本報告提供全球免疫抑制劑API (原料藥) 市場相關調查分析,市場規模、佔有率、預測,各市場區隔分析,競爭分析,市場趨勢的變化,新興機會相關的系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球免疫抑制劑API市場的影響

第4章 摘要整理

第5章 客戶的迴響

第6章 全球免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 產品市場地圖

第7章 亞太地區的免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 亞太地區:各國分析

第8章 歐洲的免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 歐洲:各國分析

第9章 北美的免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 北美:各國分析

第10章 南美的免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 南美:各國分析

第11章 中東、非洲的免疫抑制劑API市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 中東、非洲:各國分析

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢與趨勢

第14章 專利分析

第15章 競爭情形

第16章 策略性建議

目錄
Product Code: 4673

Global immunosuppressants API market is expected to grow at a formidable rate during the forecast period predominantly on account of continuous technological advancements in tissue engineering. Moreover, surging incidence of autoimmune disorders such as multiple sclerosis, alopecia areata and arthritis is positively impacting the growth of market. Also, increase in organ transplants such as liver & kidney transplants worldwide are further expected to bolster the growth of market over the next few years. However, certain factors that can act as major impediments to the growth of global immunosuppressants API market in the forthcoming years include high costs associated with API and lack of availability of organ donors.

The global immunosuppressants API market is segmented based on method, application, type, product, APIs, end user, and region. Based on product, the market can be categorized into tablets, capsules, liquids and injections; out of which, the tablet segment dominated the market and is expected to maintain its leading position during the forecast period as well, majorly on account of their longer shelf life coupled with cost-effective manufacturing process. Additionally, they can accommodate a higher dose of active ingredient as compared to capsules, which is further expected to boost the segmental growth over the coming years. In terms of application, the market is fragmented into autoimmune disease and organ transplant. The autoimmune disease segment held the largest market share until 2019 and is forecast to register higher growth during the forecast period, which is attributable to growing prevalence of autoimmune diseases across the globe. Based on end user, the market is categorized into biotechnology & biopharmaceutical companies, CMOs, CROs, CDMOs, and Others. Among them, the biotechnology & biopharmaceutical companies segment is projected to dominate the market over the next five years, on account of rising investments for research and developmental activities.

Major players operating in the global immunosuppressants API market include Biocon Ltd., NATCO Pharma Limited, Triveni Interchem Private Limited, Concord Biotech Ltd., RPG Life Sciences Limited, Jiangsu Jiuyang Bio-Pharmaceutical Co. Ltd, Chunghwa Chemical Synthesis & Biotech Co. Ltd., AbbVie Inc., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd. among others. Leading market players are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions, collaborations, partnership, and agreements to increase customer base and expand geographic reach.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and estimate the market size of global immunosuppressants API market from 2015 to 2018.
  • To estimate and forecast the market size of global immunosuppressants API market from 2019 to 2025.
  • To classify and forecast global immunosuppressants API market based on method, application, type, product, APIs, end user, and regional distribution.
  • To identify dominant region or segment in the global immunosuppressants API market.
  • To identify drivers and challenges for global immunosuppressants API market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global immunosuppressants API market.
  • To conduct pricing analysis for global immunosuppressants API market.
  • To identify and analyze the profile of leading players operating in global immunosuppressants API market.
  • to identify key sustainable strategies adopted by market players in global immunosuppressants API market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research. TechSci Research analyzed the companies and presence of all major players operating across the globe.

TechSci Research calculated the market size of global immunosuppressants API market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Immunosuppressants API companies
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to immunosuppressants API
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, suppliers and partners, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global immunosuppressants API market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • By Method:

Synthetic Chemistry

Peptide chemistry

Fermentation

Chromatographic purification

  • By Application:

Autoimmune Disease

Organ Transplant

  • By Type:

Corticosteroids

Janus kinase inhibitor

Calcineurin inhibitors

mTOR inhibitor

IMDH inhibitor

Biologics

Monoclonal antibodies

  • By Product:

Tablets

Capsules

Liquids

Injections

  • By APIs:

Tacrolimus

Sirolimus

Everolimus

Mycophenolate Mofetil

Mycophenolate Sodium

  • By End User:

Biotechnology & Biopharmaceutical Companies

CMOs

CROs

CDMOs

Others

  • By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global immunosuppressants API market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Immunosuppressants API Market

4. Executive Summary

5. Voice of Customer

6. Global Immunosuppressants API Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method (Synthetic Chemistry, Peptide chemistry, Fermentation, Chromatographic purification)
    • 6.2.2. By Application (Autoimmune Disease, Organ Transplant)
    • 6.2.3. By Type (Corticosteroids, Janus kinase inhibitor, Calcineurin inhibitors, mTOR inhibitor, IMDH inhibitor, Biologics, Monoclonal antibodies)
    • 6.2.4. By Product (Tablets, Capsules, Liquids, Injections)
    • 6.2.5. By APIs (Tacrolimus, Sirolimus, Everolimus, Mycophenolate Mofetil (MMF), Mycophenolate Sodium (MPA))
    • 6.2.6. By End User (Biotechnology & Biopharmaceutical Companies, CMOs, CROs, CDMOs, Others)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. Asia-Pacific Immunosuppressants API Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By Application
    • 7.2.3. By Type
    • 7.2.4. By Product
    • 7.2.5. By APIs
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Immunosuppressants API Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Type
        • 7.3.1.2.4. By Product
        • 7.3.1.2.5. By APIs
        • 7.3.1.2.6. By End User
    • 7.3.2. India Immunosuppressants API Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Type
        • 7.3.2.2.4. By Product
        • 7.3.2.2.5. By APIs
        • 7.3.2.2.6. By End User
    • 7.3.3. Australia Immunosuppressants API Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Type
        • 7.3.3.2.4. By Product
        • 7.3.3.2.5. By APIs
        • 7.3.3.2.6. By End User
    • 7.3.4. Japan Immunosuppressants API Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Method
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Type
        • 7.3.4.2.4. By Product
        • 7.3.4.2.5. By APIs
        • 7.3.4.2.6. By End User
    • 7.3.5. South Korea Immunosuppressants API Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Method
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Type
        • 7.3.5.2.4. By Product
        • 7.3.5.2.5. By APIs
        • 7.3.5.2.6. By End User

8. Europe Immunosuppressants API Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By Application
    • 8.2.3. By Type
    • 8.2.4. By Product
    • 8.2.5. By APIs
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Immunosuppressants API Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Type
        • 8.3.1.2.4. By Product
        • 8.3.1.2.5. By APIs
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Immunosuppressants API Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Type
        • 8.3.2.2.4. By Product
        • 8.3.2.2.5. By APIs
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Immunosuppressants API Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Type
        • 8.3.3.2.4. By Product
        • 8.3.3.2.5. By APIs
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Immunosuppressants API Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Type
        • 8.3.4.2.4. By Product
        • 8.3.4.2.5. By APIs
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Immunosuppressants API Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Type
        • 8.3.5.2.4. By Product
        • 8.3.5.2.5. By APIs
        • 8.3.5.2.6. By End User

9. North America Immunosuppressants API Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By Application
    • 9.2.3. By Type
    • 9.2.4. By Product
    • 9.2.5. By APIs
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Immunosuppressants API Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Type
        • 9.3.1.2.4. By Product
        • 9.3.1.2.5. By APIs
        • 9.3.1.2.6. By End User
    • 9.3.2. Mexico Immunosuppressants API Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Type
        • 9.3.2.2.4. By Product
        • 9.3.2.2.5. By APIs
        • 9.3.2.2.6. By End User
    • 9.3.3. Canada Immunosuppressants API Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Type
        • 9.3.3.2.4. By Product
        • 9.3.3.2.5. By APIs
        • 9.3.3.2.6. By End User

10. South America Immunosuppressants API Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By Application
    • 10.2.3. By Type
    • 10.2.4. By Product
    • 10.2.5. By APIs
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Immunosuppressants API Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Type
        • 10.3.1.2.4. By Product
        • 10.3.1.2.5. By APIs
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Immunosuppressants API Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Type
        • 10.3.2.2.4. By Product
        • 10.3.2.2.5. By APIs
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Immunosuppressants API Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Type
        • 10.3.3.2.4. By Product
        • 10.3.3.2.5. By APIs
        • 10.3.3.2.6. By End User

11. Middle East and Africa Immunosuppressants API Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Type
    • 11.2.2. By Source
    • 11.2.3. By Method
    • 11.2.4. By Technology
    • 11.2.5. By Application
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Immunosuppressants API Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Method
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Type
        • 11.3.1.2.4. By Product
        • 11.3.1.2.5. By APIs
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Immunosuppressants API Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Method
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Type
        • 11.3.2.2.4. By Product
        • 11.3.2.2.5. By APIs
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Immunosuppressants API Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Method
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Type
        • 11.3.3.2.4. By Product
        • 11.3.3.2.5. By APIs
        • 11.3.3.2.6. By End User
    • 11.3.4. Kuwait Immunosuppressants API Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Method
        • 11.3.4.2.2. By Application
        • 11.3.4.2.3. By Type
        • 11.3.4.2.4. By Product
        • 11.3.4.2.5. By APIs
        • 11.3.4.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Patent Analysis

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Players Profiled (Leading Companies)
    • 15.2.1. Biocon Ltd.
    • 15.2.2. NATCO Pharma Limited
    • 15.2.3. Triveni Interchem Private Limited
    • 15.2.4. Concord Biotech Ltd.
    • 15.2.5. RPG Life Sciences Limited
    • 15.2.6. Jiangsu Jiuyang Bio-Pharmaceutical Co. Ltd
    • 15.2.7. Chunghwa Chemical Synthesis & Biotech Co. Ltd.
    • 15.2.8. AbbVie Inc.
    • 15.2.9. Pfizer Inc.
    • 15.2.10. Zhejiang Hisun Pharmaceutical Co Ltd

16. Strategic Recommendations